Monthly Archives: February 2012
Bristol-Myers Squibb and Duke Translational Medicine Institute broaden collaboration
Bristol-Myers Squibb and Duke Translational Medicine Institute have announced the formation of a strategic relationship to broaden interactions between the two organizations. According to the organisations the relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology, and … Continue reading
Filed under alliances
Forest Laboratories and Gedeon Richter announce positive results in Phase III trials for cariprazine
Forest Laboratories and Gedeon Richter have announced positive top-line results in two Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia. Cariprazine is also currently being investigated in clinical studies for patients with bipolar … Continue reading
Filed under licensing
Angiochem signs $300 million collaboration with GlaxoSmithKline
Angiochem has announced that it has signed a global collaboration with GlaxoSmithKline to discover, develop and commercialize treatments for lysosomal storage diseases. Under the collaboration agreement, Angiochem will create new compounds (EPiC-enzymes) intended to restore enzyme function in the central … Continue reading
Filed under alliances
MorphoSys signs protein engineering agreement
MorphoSys has announced the signing of a protein engineering agreement with a large bio-pharmaceutical company. The non-exclusive license agreement covers the delivery of multiple Slonomics®-based DNA libraries. The libraries will encode a broad range of protein classes, excluding antibodies, and … Continue reading
Filed under alliances
Dako signs new collaboration with Amgen
Dako has announced that it has entered into a new collaboration agreement with Amgen on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development. In January 2012, Dako announced a collaboration agreement with Amgen … Continue reading
Filed under alliances
Ligand Pharmaceuticals signs $76 million collaboration with Retrophin
Ligand Pharmaceuticals and Retrophin have announced that they have entered into an agreement in which Ligand has licensed rights to DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors) to Retrophin. Under the terms of the agreement, Ligand … Continue reading
Filed under alliances
Satori Pharmaceuticals raises additional $15 million in fundig
Satori Pharmaceuticals, a developer of life changing therapeutics for Alzheimer’s disease, has announced that it has raised an additional $15 million in financing. Current investors InterWest Partners, New Enterprise Associates and Prospect Venture Partners co-led the round. Prior to this … Continue reading
Filed under funding
Auxilium sell Xiaflex rights to Actelion Pharmaceuticals
Auxilium has announced that Actelion Pharmaceuticals has bought the rights to sell Xiaflex in Australia, Brazil, Canada and Mexico once it is approved in those markets. The agreement also covers the use of Xiaflex to treat Peyronie’s disease. Actelion is … Continue reading
Filed under licensing
Roche and Life Technologies sign PCR licencing agreement
Roche and Life Technologies Corporation have announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications. Under the agreements, Roche has granted LTC an in vitro diagnostics product license to … Continue reading
Filed under licensing
Collegium Pharmaceutical raises $22.5 million
Collegium Pharmaceutical has announced that it has raised $22.5 million in a Series B financing round led by Longitude Capital and Skyline Ventures. Series A investors Frazier Healthcare Ventures and Boston Millennia Partners also participated in the round. The Series … Continue reading
Filed under funding
